{"organizations": [], "uuid": "8d71bea2aa6dc60b47a09bf7fcee5c7b4d87e040", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180215.html", "section_title": "Archive News &amp; Video for Thursday, 15 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-arrowhead-pharmaceuticals-receives/brief-arrowhead-pharmaceuticals-receives-orphan-drug-designation-for-aro-aat-idUSFWN1Q51EV", "country": "US", "domain_rank": 408, "title": "BRIEF-Arrowhead Pharmaceuticals Receives Orphan Drug Designation For ARO-AAT", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.046, "site_type": "news", "published": "2018-02-16T04:54:00.000+02:00", "replies_count": 0, "uuid": "8d71bea2aa6dc60b47a09bf7fcee5c7b4d87e040"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-arrowhead-pharmaceuticals-receives/brief-arrowhead-pharmaceuticals-receives-orphan-drug-designation-for-aro-aat-idUSFWN1Q51EV", "ord_in_thread": 0, "title": "BRIEF-Arrowhead Pharmaceuticals Receives Orphan Drug Designation For ARO-AAT", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "arrowhead pharmaceuticals inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "arrowhead pharma", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 15 (Reuters) - Arrowhead Pharmaceuticals Inc:\n* ARROWHEAD PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FOR ARO-AAT\n* ARROWHEAD PHARMA- U.S. FDA GRANTED ORPHAN DRUG DESIGNATION TO ARO-AAT FOR TREATMENT OF A RARE GENETIC LIVER DISEASE Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-16T04:54:00.000+02:00", "crawled": "2018-02-16T17:05:05.054+02:00", "highlightTitle": ""}